Takeda's dengue vaccine wins EU approval




  • In US
  • 2022-12-08 12:01:08Z
  • By Reuters
 

By Natalie Grover

LONDON (Reuters) -Japanese company Takeda's dengue vaccine was authorised for use in the European Union on Thursday, making it the second approved vaccine for the mosquito-borne disease that causes millions of infections annually.

The vaccine, branded QDENGA, is designed for use those aged 4 and older to prevent any of the four so-called serotypes of dengue.

There are no antivirals or specific treatments for the flu-like viral disease. While the illness is mostly mild, some people can develop life-threatening complications. Between 20,000 to 25,000 people, mostly children, die each year, according to the World Health Organization.

QDENGA follows Sanofi's Dengvaxia, which was the world's first dengue vaccine and which secured its first approval in 2015.

The use of the French drugmaker's vaccine was scaled back considerably after the company disclosed in 2017 that it increased the risk of severe disease in 'seronegative' children - those who had no prior dengue exposure when they got the shot

Takeda's vaccine is based on a dengue 2 virus, with DNA from the other three serotypes added in. Data from a pivotal trial has shown the vaccine can induce immune responses to a varied degree against all four dengue types.

Compared to Dengvaxia, Takeda's vaccine shows wider protection for young children and people older than 45 years old, EU health regulators said in October when they recommended authorising QDENGA.

The Takeda vaccine has also been approved in Indonesia, while US regulators are reviewing QDENGA on a priority basis.

Takeda expects its vaccine to generate $700 million to $1.6 billion in sales over the course of several years, Gary Dubin, president of Takeda's global vaccine business, told Reuters earlier this year.

(Reporting by Natalie Grover in LondonEditing by Jason Neely and Frances Kerry)

COMMENTS

More Related News

Sanofi
Sanofi's and Regeneron's Dupixent wins new stage of EU regulatory approval
  • US
  • 2023-01-27 06:37:50Z

Healthcare companies Sanofi and Regeneron said on Friday the European Union's medicines regulator had given a new stage of approval for their Dupixent...

Ease capital rules on EU banks to boost lending, banking industry says
Ease capital rules on EU banks to boost lending, banking industry says

Banks in the European Union could increase lending by almost a third if regulators applied capital requirements in the same way as their U.S. counterparts, a...

Hunt to Rule Out Tax Cuts While Touting UK
Hunt to Rule Out Tax Cuts While Touting UK's Brexit Potential

(Bloomberg) -- Chancellor of the Exchequer Jeremy Hunt is expected to disappoint investors and his critics in the UK ruling party Friday by rejecting calls...

Is UK being left behind in global climate investment battle?
Is UK being left behind in global climate investment battle?

The future of the planet and the global economy are entwined in a potentially risky geopolitical game.

Populist billionaire vies with ex-general for top Czech post
Populist billionaire vies with ex-general for top Czech post
  • US
  • 2023-01-26 07:51:38Z

A retired army general who backs military support for Ukraine and a euroskeptic billionaire who has questioned NATO's collective defense clause are...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: US